How much revenue does Hunan Jiudian Pharmaceutical make?

Hunan Jiudian Pharmaceutical reported 2.93 billion CNY in revenue for fiscal year 2024, up 8.8% from 2.69 billion CNY in fiscal year 2023. In Q2 2025 revenue was 815.92 million CNY.

Where does Hunan Jiudian Pharmaceutical make most of its revenue?

East China: 36% of revenue by region in fiscal year 2025, followed by Central China (17%).

What companies are similar to Hunan Jiudian Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hainan Haiyao Co., Ltd. (000566.SZ), Youcare Pharmaceutical Group Co., Ltd. (688658.SS), Beijing SL Pharmaceutical Co., Ltd. (002038.SZ), Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ).

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ) Stock

About Hunan Jiudian Pharmaceutical Co., Ltd.

Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers chemical drug preparations, active pharmaceutical ingredients (APIs), pharmaceutical excipients, traditional Chinese medicine, health foods, and rehabilitation and wellness products. Its products portfolio includes loxoprofen sodium gel patches, ...

At a glance

Hunan Jiudian Pharmaceutical reported revenue of 2.93 billion CNY for fiscal year 2024, up 8.8% from fiscal year 2023, and net income of 512.38 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 815.92 million CNY, up 5.2% from a year before. East China was its largest region in fiscal year 2025, with 36% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.